¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug development and industrial pharmacy."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • drug reaction
    ¾à¹°¹ÝÀÀ
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • drug therapy
    ¾à¹°¿ä¹ý
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • drug treatment
    ¾à¹°Ä¡·á
  • drug trial
    ¾à¹°½ÃÇè
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • drug-fast
    ¾à¹°³»¼º-
  • drug-induced
    ¾à¹°À¯¹ß-
  • drug-induced hemolysis
    ¾à¹°À¯¹ß¿ëÇ÷
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • new drug application
    ½Å¾àÇã°¡½Åû
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug
    ÀÎÁö±â´ÉȰ¼ºÁ¦
  • common drug
    º¸Åë¾à
  • crude drug
    Á¶¾à
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • drug-induced immune complex
    ¾àÁ¦À¯¹ß¸é¿ªº¹ÇÕü
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • drug of choice
    ÀÏÂ÷¼±Åþà
  • drug-fast
    ¾àÁ¦³»¼º-
  • drug-induced
    ¾à¹°À¯¹ß-, ¾àÁ¦À¯¹ß-
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • designer drug
    º¯Á¶¾à¹°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • antiseizure drug
    Ç×°æ·Ã¾à(ù÷ÌâÕýå·).
  • antiseptic drug
    ¹æºÎ¾à(¡­¾à).
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇ쟾à.
  • antispirochetic drug
    Ç×½ºÇÇ·ÎÇ쟾à.
  • antithyroid drug
    Ç×°©»ó¼±¾à(¡­å·).
  • antituberculosis drug
    Ç×°áÇÙ¾à(Á¦)
  • antiviral agent =a. drug
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ.
  • application of drug in root canal
    ±Ù°ü÷¾à¹ý(ÐÆÎ·ôäå·Ûö).
  • arsenic drug
    ºñ¼Ò¾à(Ý÷áÈå·).
  • hallucinogenic drug See hallucinogen
    ȯ°¢Á¦(ü³ÊÆð¥)
  • hematinic drug
    Á¶Ç÷¾à(ðãúìå·).
  • hematological drug
    Ç÷¾×ÀÛ¿ë¾à(úìäûíÂéÄå·).
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦.
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¼º ¾àÁø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • et al ; and others
    µé, µî. tat<ºÒ>[ÀÇ]»óÅÂ(ßÒ÷¾),
  • et al ; and others
    µé, µî. tat<ºÒ>[ÀÇ]»óÅÂ(ßÒ÷¾), ¼ÒÁú(áÈòõ). tat crible<ºÒ>[¹Ì»ý]»ç»óÅÂ(ÞèßÒ÷¾). tat dexcitation loca
  • explosion and fire hazard
    Æø¹ßÀÎÈ­¼º À§Çè.
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⼺ ¸¸¼º ¿øÆÇ»ó ż±¾ç ÇǺο°
  • familial fructose and galactose intol
    °¡Á·¼º ÇÁ·°Åä¿À½º ¹× °¥¶ôÅä ¿À½º
  • familial fructose and galactose intolerance
    °¡Á·¼º ÇÁ·°Åä¿À½º ¹× °¥¶ôÅä ¿À½º ºÒ³»Àμº(¡­ÝÕÒ±ìÑàõ).
  • feeding and eating disorder
    ¸ÔÀÌ±â ¹× ¸Ô±âÀå¾Ö(º´),¼·½ÄÀå¾Ö(º´)
  • flexure of wrist and hand
  • fluid and hemodynamic derangements
    ü¾× ¹×, Ç÷¿ªÇÐÀå¾Ö
  • fold and fossa
    º¹¸·ÁÖ¸§°ú º¹¸·¿À¸ñ
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´
  • foot and mouth disease
    ±¸Àúº´
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´.
  • foot-and-mouth disease
    ±¸Á¦¿ª (Ï¢ð´æ¹)
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
AAIN American Association of Industrial Nurses
ACGIH American Conference of Governmental Industrial Hygienists
AIHA American Industrial Hygiene Association; autoimmune hemolytic anemia
AIHC American Industrial Health Conference
BIBRA British Industrial Biological Research Association
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DARP Drug Abuse Reporting Program
DATOS Drug Abuse Treatment Outcome Study
DAWN Drug Abuse Warning Network
DEA Drug Enforcement Administration
DIC Drug Information Center
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiseborrheic drug
    Ç×Áö·ç ¾à
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇìŸ ¾à
  • antithyroid drug
    Ç×°©»ó¼± ¾à
  • bioreductive drug
    »ýü ȯ¿ø¼º ¾àÁ¦
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • cholinergic drug
    Äݸ° ÀÛ¿ë ¾à
  • common drug
    º¸Åë ¾à
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • designer drug
    º¯Á¶ ¾à¹°, ³²¿ë ¾à¹°
  • doping : the action of administering a drug to someone before a sports event
    originally to a horse before a race
    ; the substance thus administered.
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
    µ¿ÀǾî=medicine. 1. º´À̳ª »óó¸¦ Ä¡·áÇϱâ À§ÇØ ¸Ô°Å³ª ¹Ù¸£°Å³ª ÁÖ»çÇÏ´Â ¹°Áú
  • drug abstinence
    ¾à¹° ±Ý´Ü, ±Ý´Ü
  • drug acne
    ¾à¹°¼º ¿©µå¸§
  • drug addiction
    ¸¶¾à »ó½À, ¾à¹° ½À°ü¼º Áßµ¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
drug holiday Interval when a chronically medicated patient temporarily stops taking the medication; used to allow some recuperation of normal functions, to maintain sensitivity to the drug, and to reduce the likelihood of side-effects.
(05 Mar 2000)
drug hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
(12 Dec 1998)
drug implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
(12 Dec 1998)
drug incompatibility <pharmacology> The quality of not being miscible with another given substance without a chemical change.
One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction.
(12 Dec 1998)
drug-induced cholestasis <hepatology> A condition where a drug is interfering with the normal flow of bile from the liver to the gut via the biliary tract. The end result is jaundice.
Origin: Gr. Stasis = stoppage
(27 Sep 1997)
drug-induced diarrhoea <gastroenterology> Diarrhoea may be produced by several mechanisms. Laxatives may produce diarrhoea by increasing the flow of water into the intestine or by increasing the intestinal motility.
Antibiotic medications can cause diarrhoea by killing the normal bacteria that live in the intestine and help us digest our food. Some drugs produce diarrhoea as a side effect or as drug toxicity.
(27 Sep 1997)
drug-induced disease <pharmacology> A toxic reaction to or morbid condition resulting from the administration of a drug.
(05 Mar 2000)
drug-induced eosinophilic lung disease <radiology> Diffuse reticular pattern: nitrofurantoin, Loeffler-like pattern: penicillin, sulfonamides, ASA, para-ASA, imipramine, HCTZ, cromolyn sodium see: eosinophilic lung disease
(12 Dec 1998)
drug-induced hepatitis <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug.
Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives.
(27 Sep 1997)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
drug-induced tremor <neurology, pharmacology> A drug-induced condition where there is shaking (tremor) of the extremities that is increased with purposeful movement.
Drugs known to induce tremor include: theophylline, Alupent, cyclosporine, amphetamines, lithium and caffeine.
(27 Sep 1997)
drug industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
(12 Dec 1998)
drug information services Services providing pharmaceutic and therapeutic drug information and consultation.
(12 Dec 1998)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Foreign and Commonwealth Office
    ¿Ü¹« ¿¬¹æ¼º
  • Gog and Magog
    °î°ú ¸¶°î(»çÅÁ¿¡ ¹ÌȤµÇ¾î ÇÏ´Ã ³ª¶ó¿¡ ´ëÇ×ÇÏ´Â µÎ³ª¶ó)
  • H and C
    Çì·ÎÀÎ(heroin)°ú ÄÚÄ«ÀÎ(cocaine)À» ¼¯Àº °Í
  • Hereford and Worcester
    À×±Û·£µå ¼­ºÎÀÇ ÁÖ(1974³â ½Å¼³)
  • Jekyll and Hyde
    2ÁßÀΰÝÀÚÀÇ;2Áß ÀΰÝÀûÀÎ
  • Punch and Judy
    Àͻ콺·¯¿î ¿µ±¹ÀÇ ÀÎÇü±Ø
  • R&D,R.and D.
    research and development ¿¬±¸ °³¹ß
  • Royal and Ancient
    ·Î¿­ ¾Øµå ¿¡ÀÎ¼ÇÆ® °ñÇÁ Ŭ·´(¼¼°è ÃÖ°í,1754³â °³¼³)
  • Trinidad and Tobago
    ¼­Àεµ Á¦µµ¿¡ ÀÖ´Â ¿µ¿¬¹æ³»ÀÇ µ¶¸³±¹
  • and
    ±×¸®°í;¹×;¶ÇÇÑ;±×·¯ÀÚ;±×·¯¸é;(and/or=and or(newspapers and/or magazines ½Å¹® ¹× ¶Ç´Â ÀâÁö)
  • bait and switch
    À¯ÀÎ »ó¼úÀÇ
  • beall and endall
    ¿äÁ¡;Á¤¼ö;Áß¿äºÎ
  • buck and wing
    ÈæÀÎÀÇ ´í½º¿Í ¾ÆÀÏ·£µå°èÀÇ Å¬·Î±×´í½º°¡ ¼¯ÀÎ ·ÎÅ«·ÑÀÇ ºü¸¥ ÅÇ´í½º
  • cash-and-carry
    Çö±ÝÆÇ¸Å·Î Á¡µÎ¿¡¼­ ÀεµÇÏ´Â;Çö±Ý Á¡µÎ ÆÇ¸Å(Á¡);Çö±Ý Á¡µÎ ÆÇ¸ÅÁÖÀÇ
  • cat and mouse
    °í¾çÀÌ¿Í Áã(¾ÆÀÌµé ³îÀÌÀÇ Çϳª);°í¾çÀ̰¡ Á㸦 ³î¸®µí Çϱâ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á